Heart [310] — Athena

One tablet should be taken with the and one with the evening meal to ensure proper absorption. Target Population :

Clinicians should monitor several factors to prevent adverse outcomes:

Monitor closely if the patient is also taking warfarin, as dronedarone can increase warfarin exposure. 4. Patient Monitoring ATHENA HEART [310]

: The trial established dronedarone as a rhythm-control therapy specifically aimed at reducing clinical complications rather than just maintaining sinus rhythm. 2. Dronedarone (Multaq) Usage Guide

: To determine if dronedarone could lower the risk of hospitalization due to cardiovascular events or death from any cause in patients with atrial fibrillation (AF) or atrial flutter (AFL). One tablet should be taken with the and

Based on the code , this guide provides a breakdown of the ATHENA clinical trial (A Trial with dronedarone to prevent Hospitalization or death in patients with Atrial fibrillation) and the associated use of dronedarone (brand name Multaq ) for cardiovascular health. 1. Overview of the ATHENA Trial

The official FDA label outlines critical safety measures based on ATHENA data: : Patient Monitoring : The trial established dronedarone as

: Contraindicated in patients with symptomatic heart failure or recent hospitalization for heart failure (NYHA Class IV or symptomatic Class II-III).